Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I plus N).

被引：0
|
作者：
Desai, Kunal
Rybicki, Lisa A.
Nizam, Amanda
Wood, Laura S.
Allman, Kimberly D.
Martin, Allison
Calabrese, Cassandra
Gilligan, Timothy D.
Gupta, Shilpa
Ornstein, Moshe Chaim
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17094
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma
    Kikuchi, Hiroshi
    Osawa, Takahiro
    Matsumoto, Ryuji
    Abe, Takashige
    Maruyama, Satoru
    Harabayashi, Toru
    Miyata, Haruka
    Kashiwagi, Akira
    Ikeshiro, Suguru
    Sazawa, Ataru
    Fukui, Riyo
    Morita, Ken
    Takeuchi, Ichiro
    Hori, Kanta
    Yamashita, Noboru
    Minami, Keita
    Mochizuki, Tango
    Murai, Sachiyo
    Shinohara, Nobuo
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (01) : 13.e19 - 13.e27
  • [42] Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib plus nivolumab plus /- ipilimumab
    Iannantuono, Giovanni Maria
    Chandran, Elias
    Simon, Nicholas I.
    Ley, Lisa
    Cordes, Lisa M.
    Wang, Tzu-fang
    Girardi, Daniel da Motta
    Gurram, Sandeep
    Valera, Vladimir
    Chalfin, Heather
    Parnes, Howard L.
    Nadal, Rosa
    Niglio, Scot Anthony
    Boudjadi, Salah
    Banday, Abdul Rouf
    Kydd, Andre Rashad
    Steinberg, Seth M.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
    Martini, Dylan J.
    Goyal, Subir
    Liu, Yuan
    Evans, Sean T.
    Olsen, T. Anders
    Case, Katherine
    Magod, Benjamin L.
    Brown, Jacqueline T.
    Yantorni, Lauren
    Russler, Greta Anne
    Caulfield, Sarah
    Goldman, Jamie M.
    Nazha, Bassel
    Harris, Wayne B.
    Kissick, Haydn T.
    Master, Viraj A.
    Kucuk, Omer
    Carthon, Bradley C.
    Bilen, Mehmet Asim
    ONCOLOGIST, 2021, 26 (10): : E1742 - E1750
  • [44] The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study
    Taigo Kato
    Akira Nagahara
    Norihiko Kawamura
    Wataru Nakata
    Tetsuji Soda
    Kyosuke Matsuzaki
    Koji Hatano
    Atsunari Kawashima
    Takeshi Ujike
    Ryoichi Imamura
    Kensaku Nishimura
    Shingo Takada
    Masao Tsujihata
    Seiji Yamaguchi
    Tetsuya Takao
    Kazuo Nishimura
    Norio Nonomura
    Motohide Uemura
    International Journal of Clinical Oncology, 2021, 26 : 954 - 961
  • [45] The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study
    Kato, Taigo
    Nagahara, Akira
    Kawamura, Norihiko
    Nakata, Wataru
    Soda, Tetsuji
    Matsuzaki, Kyosuke
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Imamura, Ryoichi
    Nishimura, Kensaku
    Takada, Shingo
    Tsujihata, Masao
    Yamaguchi, Seiji
    Takao, Tetsuya
    Nishimura, Kazuo
    Nonomura, Norio
    Uemura, Motohide
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (05) : 954 - 961
  • [46] COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS
    Klijn, S.
    Van de Wetering, G.
    Malcolm, B.
    Dale, P.
    Pompen, M.
    Stevanovic, J.
    VALUE IN HEALTH, 2018, 21 : S46 - S46
  • [47] Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study
    Koichi Kido
    Shingo Hatakeyama
    Kazuyuki Numakura
    Toshikazu Tanaka
    Masaaki Oikawa
    Daisuke Noro
    Shogo Hosogoe
    Shintaro Narita
    Takamitsu Inoue
    Takahiro Yoneyama
    Hiroyuki Ito
    Shoji Nishimura
    Yasuhiro Hashimoto
    Toshiaki Kawaguchi
    Tomonori Habuchi
    Chikara Ohyama
    International Journal of Clinical Oncology, 2021, 26 : 154 - 162
  • [48] Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma (mRCC) using real-world data.
    Geynisman, Daniel M.
    Faccone, Jillian
    Zhang Ying
    Ejzykowicz, Flavia
    Stwalley, Brian
    Hamilton, Melissa
    Le, Trong Kim
    Huo, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [49] Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
    Kobayashi, Kazuo
    Iikura, Yusuke
    Hiraide, Makoto
    Yokokawa, Takashi
    Aoyama, Takeshi
    Shikibu, Sari
    Hashimoto, Koki
    Suzuki, Kenichi
    Sato, Hitoshi
    Sugiyama, Erika
    Tajima, Masataka
    Hama, Toshihiro
    IN VIVO, 2020, 34 (05): : 2647 - 2652
  • [50] Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study
    Kido, Koichi
    Hatakeyama, Shingo
    Numakura, Kazuyuki
    Tanaka, Toshikazu
    Oikawa, Masaaki
    Noro, Daisuke
    Hosogoe, Shogo
    Narita, Shintaro
    Inoue, Takamitsu
    Yoneyama, Takahiro
    Ito, Hiroyuki
    Nishimura, Shoji
    Hashimoto, Yasuhiro
    Kawaguchi, Toshiaki
    Habuchi, Tomonori
    Ohyama, Chikara
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 154 - 162
12345